A double-monoclonal immunoenzymometric assay for alpha 1-fetoprotein modified for increased analytical precision.
We modified a one-step, two-site, double monoclonal immunoenzymometric assay (Abbott Laboratories) for serum alpha1-fetoprotein (AFP) to increase its sensitivity and improve test precision at the low end. We increased sample size, incubation interval, and reaction time and temperature, and decreased the final reaction volume. Interassay CVs for the modified method ranged from 6.2 to 8.0% for mean concentrations of AFP in serum of 5.2 to 34.2 micrograms/L--substantially better than those for the unmodified monoclonal method--and agreed well with those of the comparison method (modified Abbott polyclonal immunoenzymometric assay). AFP values by the modified monoclonal procedure (y) correlated well with results by the polyclonal method (x): y = 0.983x + 1.84 micrograms/L (r = 0.927, n = 59). The detection limit of the modified monoclonal test was 0.2 microgram/L, as compared with 1.0 and 1.4 micrograms/L, respectively, for the modified polyclonal and the unmodified monoclonal procedures. We recommend using the modified monoclonal method for monitoring cancer patients with low tumor burden.
D000911:Antibodies, Monoclonal; D006801:Humans; D007124:Immunoenzyme Techniques; D008722:Methods; D009369:Neoplasms / Q000097:blood; D012016:Reference Values; D000509:alpha-Fetoproteins / Q000097:blood*
D000911:Antibodies, Monoclonal; D000509:alpha-Fetoproteins